


Listing of Claims

Claims 1-8 (cancelled)

Claim ~~9~~¹ (previously amended) A method of suppressing excessive levels of GH in a patient in need of same which comprises administering to said patient an effective amount of a peptide selected from the group having the formulae:



wherein X is PhAc, IndAc, or Nac,

R¹ is Tyr or His,

R² is D-Arg [or D-Cit],

R⁵ is Ile or Val,

R⁶ is Phe, Nal or Phe(Y), in which Y= Cl,

R⁸ is Asn, Gln, Ala, or D-Asn,

R⁹ is Arg, Har, Lys, Orn, D-Arg, D-Har, D-Lys, D-Orn, Cit, Nle, Tyr (Me), Ser, Ala or

Aib,

R¹⁰ is Tyr or or Tyr(Me),

R¹² is Lys,

R¹³ is Val or Nle,

R¹⁴ is Leu or Nle,

R¹⁵ is Gly, Ala, Abu, Nle or Gln,

R¹⁶ is Gln or Arg,

R¹⁸ is Ser or Nle,

R¹⁹ is Ala ,

R²¹ is Lys ,

R²² is Leu, Ala or Aib,

RECEIVED

MAY 27 2003

TECH CENTER 1600/2900

R²⁷ is Met, Leu, Nle, Abu, or D-Arg,

R²⁸ is Arg, D-Arg, or Ser,

R²⁹ is Arg, D-Arg, Har or D-Har,

provided that where R⁹ and R²⁸ are Ser, R²⁹ is other than Arg or Har,
and pharmaceutically acceptable salts thereof.

Claim 10. (previously amended) A method of treating a patient having a cancer carrying receptors for IGF-I or -II which comprises administering to said patient an effective amount of a peptide selected from the group having the formulae:

X-R¹-R²-Asp-Ala-R⁵-R⁶-Thr-R⁸-R⁹-R¹⁰-Arg-R¹²-R¹³-R¹⁴-R¹⁵-R¹⁶-Leu-R¹⁸-R¹⁹-Arg-R²¹-R²²-
Leu-Gln-Asp-Ile-R²⁷-R²⁸-R²⁹-NH₂

wherein X is PhAc, IndAc, or Nac,

R¹ is Tyr or His,

R² is D-Arg [or D-Cit],

R⁵ is Ile or Val,

R⁶ is Phe, Nal or Phe(Y), in which Y= Cl,

R⁸ is Asn, Gln, Ala, or D-Asn,

R⁹ is Arg, Har, Lys, Orn, D-Arg, D-Har, D-Lys, D-Orn, Cit, Nle, Tyr (Me), Ser, Ala or

Aib,

R¹⁰ is Tyr or or Tyr(Me),

R¹² is Lys,

R¹³ is Val or Nle,

R¹⁴ is Leu or Nle,

R¹⁵ is Gly, Ala, Abu, Nle or Gln,

R¹⁶ is Gln or Arg,

R¹⁸ is Ser or Nle,

R¹⁹ is Ala ,

R²¹ is Lys ,

R²² is Leu, Ala or Aib,

R²⁷ is Met, Leu, Nle, Abu, or D-Arg,

R²⁸ is Arg, D-Arg, or Ser,

R²⁹ is Arg, D-Arg, Har or D-Har,

provided that where R⁹ and R²⁸ are Ser, R²⁹ is other than Arg or Har,
and pharmaceutically acceptable salts thereof .

Claim ³/₁₁. (currently amended) A [a] method for inhibiting IGF-II levels in tumors (cancers) and the expression of mRNA for IGF-II in the same tumors in patients having such tumors, which comprises administering to said patient an effective amount a peptide selected from the group having the formulae:

X-R¹-R²-Asp-Ala-R⁵-R⁶-Thr-R⁸-R⁹-R¹⁰-Arg-R¹²-R¹³-R¹⁴-R¹⁵-R¹⁶-Leu-R¹⁸-R¹⁹-Arg-R²¹-R²²-
Leu-Gln-Asp-Ile-R²⁷-R²⁸-R²⁹-NH₂

wherein X is PhAc, IndAc, or Nac,

R¹ is Tyr or His,

R² is D-Arg [or D-Cit],

R⁵ is Ile or Val,

R⁶ is Phe, Nal or Phe(Y), in which Y= Cl,

R⁸ is Asn, Gln, Ala, or D-Asn,

R⁹ is Arg, Har, Lys, Orn, D-Arg, D-Har, D-Lys, D-Orn, Cit, Nle, Tyr (Me), Ser, Ala or Aib,

R¹⁰ is Tyr or or Tyr(Me),

R¹² is Lys,

R¹³ is Val or Nle,

R¹⁴ is Leu or Nle,

R¹⁵ is Gly, Ala, Abu, Nle or Gln,

R¹⁶ is Gln or Arg,

R¹⁸ is Ser or Nle,

R¹⁹ is Ala ,

R²¹ is Lys ,

R²² is Leu, Ala or Aib,

R²⁷ is Met, Leu, Nle, Abu, or D-Arg,

R²⁸ is Arg, D-Arg, or Ser,

R²⁹ is Arg, D-Arg, Har or D-Har,

provided that where R⁹ and R²⁸ are Ser, R²⁹ is other than Arg or Har,
and pharmaceutically acceptable salts thereof .

Claim ~~12~~⁴ (previously added) The method of claim ~~8~~¹ which comprises administering a compound having the formula [PhAc⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 1.

Claim ~~13~~⁵ (previously added) The method of claim ~~9~~¹ which comprises administering a compound having the formula [PhAc⁰, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 3.

Claim ~~14~~⁶ (previously added) The method of claim ~~10~~⁷ which comprises administering a compound having the formula [PhAc⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 1.

Claim ~~15~~¹ (previously added) The method of claim ~~10~~⁷ which comprises administering a compound having the formula [PhAc⁰, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 3.

Claim ¹~~16~~. (previously added) The method of claim ³~~11~~ which comprises administering a compound having the formula [PhAc⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 1.

Claim ¹~~17~~. (previously added) The method of claim ³~~11~~ which comprises administering a compound having the formula [PhAc⁰, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 3.